Losartan Potassium
Product Images NDC 75921-409

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 75921-409). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Life Line Home Care Services, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan 50mg #30 Label (Losartan 50mg)

Losartan Potassium 50 mg tablet label from Life Line Home Care Services, Inc. The label includes quantity (30 tablets), manufacturer Torrent, manufacturer lot number B0501002B, and expiration date 06/30/13. Barcode and manufacturing details are also shown.*

FDA Label Image

Structural Formula (Losartanpotassiumusp Figure 01)

Chemical structure of Losartan Potassium, an active pharmaceutical ingredient used in antihypertensive medications. The diagram depicts the molecular arrangement including the chlorinated pyrimidine ring and potassium ion.*

FDA Label Image

Image (Losartanpotassiumusp Figure 02)

A line graph comparing the percentage of patients with the primary endpoint over study months between Atenolol (dotted line) and Losartan Potassium Tablets (solid line). The graph shows a gradual increase over time, indicating an adjusted risk reduction of 13% with Losartan Potassium Tablets, with a p-value of 0.021.*

FDA Label Image

Image (Losartanpotassiumusp Figure 03)

A line chart comparing the percentage of patients with fatal or non-fatal stroke over study months for Losartan Potassium Tablets versus Atenolol. The graph shows cumulative risk over time, with Losartan Potassium Tablets having a lower percentage than Atenolol, indicating a 25% adjusted risk reduction (p=0.001) during the study period.*

FDA Label Image

Image (Losartanpotassiumusp Figure 04)

This figure presents a forest plot comparing primary endpoint events between Losartan Potassium tablets and Atenolol, showing hazard ratios with 95% confidence intervals across various demographic subgroups including age, gender, race, ISH status, diabetes, and history of cardiovascular disease. Two endpoints are depicted: primary composite and stroke (fatal/non-fatal). The plot visually contrasts event rates and the favorability of each treatment.*

FDA Label Image

Image (Losartanpotassiumusp Figure 05)

A line graph comparing the percentage of patients with an event over 48 months between those taking Losartan Potassium tablets and a placebo. The graph shows cumulative event rates with solid and dotted lines representing Losartan Potassium and placebo groups respectively, and includes a risk reduction value of 16.1% and a p-value of 0.022.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.